Tamburrini L R, Di Monte M, Malagoli M
Cattedra di Geriatria, Università degli Studi di Trieste.
Minerva Med. 1991 Jul-Aug;82(7-8):483-8.
The paper confirms the value of captopril in a sample group of 20 elderly patients (mean age 72.9 years) affected by overall cardiac decompensation in more or less clinically evident phases. All patients were randomly selected and received ACE-inhibition treatment for six months; doses of 25 mg or 50 mg captopril were given twice a day and all other drugs were suspended except for digitalis which was used by all patients without success. During the course of the trial the most important clinical results were the reduction of systemic blood pressure due to the diminution of peripheral resistance, the reduction of postload and ventricular filling pressure, and the consequent improvement of cardiac decompensation. All elderly patients treated in this manner experienced a stable improvement in the quality of life, with a considerable reduction in the consumption of diuretics to which they are particularly vulnerable. Following a broad ranging comparison with other reports, the Authors conclude that captopril is a geriatric drug which should be used as early as possible during the phases of latent cardiac insufficiency or at the first signs of a hypertensive crisis.
该论文证实了卡托普利在一组20名老年患者（平均年龄72.9岁）中的价值，这些患者处于不同临床明显阶段的全心力衰竭状态。所有患者均随机选取，并接受了六个月的血管紧张素转换酶抑制治疗；卡托普利剂量为25毫克或50毫克，每日两次给药，除所有患者均使用但无效的洋地黄外，停用所有其他药物。在试验过程中，最重要的临床结果是由于外周阻力降低导致的系统性血压下降、后负荷和心室充盈压降低，以及随之而来的心衰改善。所有接受这种治疗方式的老年患者生活质量都有稳定改善，对他们特别易受影响的利尿剂的消耗量大幅减少。在与其他报告进行广泛比较后，作者得出结论，卡托普利是一种老年用药，应在潜在心功能不全阶段或高血压危象的最初迹象出现时尽早使用。
